Trial Profile
AVENuE - Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms AVENuE
- 05 Dec 2023 Planned End Date changed from 1 Nov 2023 to 30 May 2025.
- 05 May 2022 Planned End Date changed from 1 Nov 2024 to 1 Nov 2023.
- 05 May 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Jul 2022.